Lineage

Jan 5, 2021 Pub. L. 116–291 Enacted
Jan 5, 2021 Enrolled Bill See what changed
Dec 10, 2020 Referred in Senate Received; read twice and referred to the Committee on Health, Education, Labor, and Pensions See what changed
Dec 9, 2020viewing Engrossed in House See what changed
Mar 28, 2019 Introduced in House Mr. Cummings (for himself, Mr. Sarbanes, and Mr. Ruppersberger) introduced the following bill; which was referred to the Committee on Energy and Commerce, and in addition to the Committees on Armed Services, and Veterans' Affairs, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned

H.R. 1966 — what changed

Henrietta Lacks Enhancing Cancer Research Act of 2019

From Introduced in House to Engrossed in House. 1 section amended between Introduced in House and Engrossed in House.

Sec. 3 GAO study on barriers to participation in federally funded cancer clinical trials by populations that have been traditionally underrepresented in such trials

(a)

In general— Not later than 2 years after the date of enactment of this Act, the Comptroller General of the United States shall—

(1)

complete a study that—

(A)

reviews what actions Federal agencies have taken to help to address barriers to participation in federally funded cancer clinical trials by populations that have been traditionally underrepresented in such trials, and identifies challenges, if any, in implementing such actions; and

(B)

identifies additional actions that can be taken by Federal agencies to address barriers to participation in federally funded cancer clinical trials by populations that have been traditionally underrepresented in such trials; and

(2)

submit a report to the Congress on the results of such study, including recommendations on potential changes in practices and policies to improve participation in such trials by such populations.

(b)

changed Inclusion of clinical trials— The study under subsection (a)(1) ~~should~~ shall include review of cancer clinical trials that are largely funded by Federal agencies, including the National Institutes of Health, the Department of Defense, the Department of Veterans Affairs, the Agency for Health Research and Quality, the Food and Drug Administration, and such other Federal agencies as the Comptroller General of the United States may identify.agencies.

H.R. 1966 — what changed

Sec. 3 GAO study on barriers to participation in federally funded cancer clinical trials by populations that have been traditionally underrepresented in such trials

Cite this provision

Incoming references